Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius BioTherapeutics received HREC approval and CTN clearance to start a Phase 1 trial for INT2104, a novel in vivo CAR therapy targeting B cell malignancies, in 4Q24. INT2104, an off-the-shelf, single-dose treatment, aims to create CAR-T and CAR-NK cells in vivo without preconditioning.
Reference News
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius BioTherapeutics received HREC approval and CTN clearance to start a Phase 1 trial for INT2104, a novel in vivo CAR therapy targeting B cell malignancies, in 4Q24. INT2104, an off-the-shelf, single-dose treatment, aims to create CAR-T and CAR-NK cells in vivo without preconditioning.